Study of IBI3028 in Participants With Locally Advanced, Unresectable, or Metastatic Solid Tumors

Sponsor
Innovent Biopharmaceutical Technology (Hangzhou) Co., LTD.
Study ID
NCT07589205
Phase
PHASE1
Status
Recruiting
Apply to this trial

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • Drug: IBI3028 — DRUG
    Recombinant anti-EGFR（Epidermal growth factor receptor） and c-Met antibodies-dual-payload conjugate for injection

Study Details

This is a phase 1 multi-center, open-label study evaluating IBI3028 Treatment in participants with locally advanced, unresectable, or metastatic solid tumors

Key Dates

First listed
May 15, 2026
Start date
Mar 31, 2026
Status verified
May 2026
Primary completion
Jun 30, 2027
Completion
Jun 30, 2028

Study Design

Enrollment
493 participants (estimated)
Allocation
NA
Intervention model
SEQUENTIAL
Primary purpose
TREATMENT

Arms

  • Experimental: Drug: IBI3028
    IBI3028 will be dosed until disease progression, toxicity intolerance, starting of new systemic anti-cancer treatment, withdrawal of consent, occurrence of other reasons for discontinuing study therapy, or treatment duration reaching the maximum of 24 months, whichever occurs first.

Primary Outcome Measure

Numbers of subjects with adverse events [ Time Frame: Up to 3 years ]

Central Contacts

Find similar trials

Nationwide
Colorectal cancer trialsHead and neck cancer trialsLung cancer trialsPancreatic cancer trialsOncology trialsGI oncology trialsENT trialsLung oncology trialsLung disease trials

Related Studies